Introduction Objectives
Study Design Recruitment of cases
Lipid Clinics Participating in the study Follow-up
What is being measured? Surveys Safeheart

The general objectives of this project are:

  • 1) to determine the absolute and relative mortality from all causes and from cardiovascular disease in treated FH patients.
  • 2) to analyse the relative risk of non-fatal cardiovascular events in this population
  • 3) to study the prognostic role of classic risk factors, dietary habits and genetic variability associated with favourable or unfavourable evolution in FH clinical expression.
  • 4) to analyse the role of LDL-r mutation types in determining the risk of coronary disease.
  • 5) To estimate the long-term quality of life of FH subjects and their families.

Los comentarios están cerrados.